Brasofensine: Difference between revisions

Latest revision as of 04:03, 13 February 2025

Brasofensine[edit]

Brasofensine is a pharmacological compound that has been investigated for its potential use in the treatment of Parkinson's disease and other neurological disorders. It is classified as a dopamine reuptake inhibitor, which means it works by blocking the reabsorption of dopamine into neurons, thereby increasing the availability of dopamine in the synaptic cleft.

Mechanism of Action[edit]

Brasofensine primarily acts by inhibiting the dopamine transporter (DAT), which is responsible for the reuptake of dopamine from the synaptic cleft back into the presynaptic neuron. By blocking this transporter, brasofensine increases the concentration of dopamine in the synaptic cleft, enhancing dopaminergic neurotransmission. This mechanism is particularly beneficial in conditions like Parkinson's disease, where there is a deficiency of dopamine in the striatum.

Potential Therapeutic Uses[edit]

Parkinson's Disease[edit]

Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra. The resulting dopamine deficiency leads to the hallmark symptoms of Parkinson's, including tremor, rigidity, and bradykinesia. By increasing dopamine levels, brasofensine has the potential to alleviate these symptoms.

Other Neurological Disorders[edit]

In addition to Parkinson's disease, brasofensine has been studied for its effects on other neurological conditions that involve dopaminergic dysfunction, such as attention deficit hyperactivity disorder (ADHD) and certain forms of depression. However, its efficacy and safety in these conditions require further investigation.

Development and Research[edit]

Brasofensine was initially developed by NeuroSearch, a Danish pharmaceutical company, and underwent several clinical trials to assess its safety and efficacy. Despite promising preclinical results, the development of brasofensine was eventually discontinued due to various challenges encountered during clinical trials, including issues related to efficacy and side effects.

Chemical Properties[edit]

Brasofensine is a synthetic compound with a complex chemical structure, as depicted in the accompanying image. Its molecular formula is C16H23NO2, and it belongs to the class of compounds known as piperidines.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Brasofensine''' (development code name: NS-2214) is a [[monoamine reuptake inhibitor]] that was initially researched as a potential treatment for [[Parkinson's disease]] and [[depression]]. However, its development was discontinued in the late phases of clinical trials due to unsatisfactory results and concerns over its safety profile. Despite its failure as a therapeutic agent, brasofensine has contributed to the understanding of the [[neurotransmitter]] systems involved in various neurological and psychiatric conditions.
+== Brasofensine ==
-==Pharmacology==
+[[File:Brasofensine.svg|thumb|right|Chemical structure of Brasofensine]]
-Brasofensine primarily acts by inhibiting the reuptake of [[dopamine]], [[norepinephrine]], and [[serotonin]], three key neurotransmitters in the brain. By blocking the reuptake of these neurotransmitters, brasofensine increases their availability in the synaptic cleft, which is thought to contribute to its therapeutic effects. Its mechanism of action is similar to that of other drugs in the class of [[monoamine reuptake inhibitors]], but with a unique pharmacological profile.
-===Mechanism of Action===
+'''Brasofensine''' is a [[pharmacological]] compound that has been investigated for its potential use in the treatment of [[Parkinson's disease]] and other [[neurological disorders]]. It is classified as a [[dopamine reuptake inhibitor]], which means it works by blocking the reabsorption of [[dopamine]] into neurons, thereby increasing the availability of dopamine in the [[synaptic cleft]].
-The drug's mechanism involves the inhibition of the [[dopamine transporter]] (DAT), [[norepinephrine transporter]] (NET), and [[serotonin transporter]] (SERT), leading to an increase in the concentrations of these neurotransmitters in the brain. This action is believed to be responsible for its potential antidepressant and antiparkinsonian effects, as both conditions are associated with dysregulation of monoaminergic systems.
-==Clinical Trials==
+== Mechanism of Action ==
-Brasofensine was subjected to several clinical trials in the 1990s to evaluate its efficacy and safety in treating Parkinson's disease and depression. In early trials, it showed promise in alleviating symptoms of Parkinson's disease, such as bradykinesia and rigidity. However, in later phase trials, the drug did not demonstrate a significant advantage over existing treatments, and concerns were raised regarding its side effect profile, particularly the risk of [[psychosis]] and cardiovascular effects.
-==Discontinuation==
+Brasofensine primarily acts by inhibiting the dopamine transporter (DAT), which is responsible for the reuptake of dopamine from the synaptic cleft back into the presynaptic neuron. By blocking this transporter, brasofensine increases the concentration of dopamine in the synaptic cleft, enhancing dopaminergic neurotransmission. This mechanism is particularly beneficial in conditions like Parkinson's disease, where there is a deficiency of dopamine in the [[striatum]].
-The development of brasofensine was ultimately discontinued due to these concerns and the lack of a clear clinical benefit over other available therapies. The discontinuation of brasofensine's development highlights the challenges in drug development, especially in the field of neurology and psychiatry, where the complexity of the diseases often makes it difficult to find effective and safe treatments.
-==Impact on Research==
+== Potential Therapeutic Uses ==
-Despite its failure as a commercial drug, the research on brasofensine has provided valuable insights into the monoaminergic systems of the brain and their role in neurological and psychiatric disorders. It has also contributed to the development of other monoamine reuptake inhibitors with improved efficacy and safety profiles.
-==See Also==
+=== Parkinson's Disease ===
-* [[Monoamine reuptake inhibitor]]
+[[Parkinson's disease]] is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the [[substantia nigra]]. The resulting dopamine deficiency leads to the hallmark symptoms of Parkinson's, including [[tremor]], [[rigidity]], and [[bradykinesia]]. By increasing dopamine levels, brasofensine has the potential to alleviate these symptoms.
+=== Other Neurological Disorders ===
+In addition to Parkinson's disease, brasofensine has been studied for its effects on other neurological conditions that involve dopaminergic dysfunction, such as [[attention deficit hyperactivity disorder]] (ADHD) and certain forms of [[depression]]. However, its efficacy and safety in these conditions require further investigation.
+== Development and Research ==
+Brasofensine was initially developed by [[NeuroSearch]], a Danish pharmaceutical company, and underwent several clinical trials to assess its safety and efficacy. Despite promising preclinical results, the development of brasofensine was eventually discontinued due to various challenges encountered during clinical trials, including issues related to efficacy and side effects.
+== Chemical Properties ==
+Brasofensine is a synthetic compound with a complex chemical structure, as depicted in the accompanying image. Its molecular formula is C16H23NO2, and it belongs to the class of compounds known as [[piperidines]].
+== Related Pages ==
+* [[Dopamine reuptake inhibitor]]
 * [[Parkinson's disease]]
-* [[Depression]]
+* [[Dopamine]]
 * [[Neurotransmitter]]
-* [[Dopamine transporter]]
-* [[Norepinephrine transporter]]
-* [[Serotonin transporter]]
-[[Category:Monoamine reuptake inhibitors]]
+[[Category:Pharmacology]]
-[[Category:Abandoned drugs]]
+[[Category:Neurology]]
-{{medicine-stub}}
+[[Category:Dopamine reuptake inhibitors]]